Oslo, Norway, 12 August 2025. EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce that clinical data from its ACTIVATE Phase 1 trial in patients with liver metastases of colorectal origin (NCT04021277) will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, taking place 17-21 October, 2025 in Berlin, Germany.
Details of the poster presentation are as follows:
Poster #: 4176
Title: First-in-Human Study of Acoustic Cluster Therapy consisting of PS101 combined with Chemotherapy and insonation in Patients with Liver Metastases of Colorectal Cancer Origin
The e-poster will be available on the Company’s website on 18 October, 2025.
About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here: www.exact-tx.com
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com